Stockscreener 앱 받기
84.75
0.06%
0.05
시간 외 거래:
84.75
전일 마감가:
$84.70
열려 있는:
$84.62
하루 거래량:
1.64M
Relative Volume:
0.45
시가총액:
$8.99B
수익:
$18.07M
순이익/손실:
$-496.39M
주가수익비율:
-16.51
EPS:
-5.1333
순현금흐름:
$-419.52M
1주 성능:
+0.71%
1개월 성능:
+1.06%
6개월 성능:
+94.02%
1년 성능:
+175.88%
1일 변동 폭
$84.61
$84.76
1주일 범위
$84.20
$84.76
52주 변동 폭
$28.73
$84.76
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
84.75 | 8.99B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-10 | 개시 | Goldman | Neutral |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - marketscreener.com
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Bank of America Corp DE Sells 85,189 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX (Crinetics Pharmaceuticals) EV-to-OCF : -18.52 (As of Aug. 16, 2026) - GuruFocus
Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Stocktwits
Vertex-Crinetics pharma merger cleared in US, Germany, Austria, Australia - MLex
Form 8K Crinetics Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances - Investing.com
Vertex to acquire Crinetics after HSR clearance; closing expected early Sept - TradingView
Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones - Stock Titan
How (CRNX) Movements Inform Risk Allocation Models - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex-Crinetics Pharmaceuticals deal receives clearance in Australia - MLex
Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD - Investing.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 12-Month HighWhat's Next? - MarketBeat
Weekly Recap: Vertex $10B deal, guidance paused and Q2 loss — Crinetics - TradingView
First Trust Advisors LP Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
California State Teachers Retirement System Boosts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FARALLON CAPITAL MANAGEMENT LLC Adds to Crinetics Pharmaceutical - GuruFocus
Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC - Stock Titan
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value - Sahm
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen - Sahm
Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD - Investing.com
Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued - finance.yahoo.com
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings - MarketBeat
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis - Yahoo Finance
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Revenue Growth Surges by 2,873% Amidst Strong Biotech Potential - DirectorsTalk Interviews
CRNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M - GuruFocus
Crinetics Pharma earnings beat by $0.08, revenue topped estimates - Investing.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Issues Earnings Results - MarketBeat
Crinetics Pharmaceuticals 2026: Revenue $25.12M, EPS ($1.14) — 10-Q Summary - TradingView
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M - marketscreener.com
Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX) - Stock Titan
Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal - The Business Journals
Janus Henderson Group PLC Has $164.23 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Bank of New York Mellon Corp Sells 46,291 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals (CRNX) holders to vote on $85-per-share cash sale to Vertex - Stock Titan
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target - Yahoo Finance
Crinetics Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Crinetics Pharmaceuticals (NASDAQ:CRNX) Cut to "Hold" at UBS Group - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vivaldi Coelho Rogerio | Director |
Jul 02 '26 |
Sale |
40.00 |
3,000 |
120,000 |
19,225 |
1.80%
1.77%
자본화:
|
볼륨(24시간):